FDA wants more data for GTx's toremifene

GTx Inc. (NASDAQ:GTXI) fell $4.42 (49%) to $4.56 on Monday after FDA issued a complete response letter for toremifene 80 mg to reduce fractures in men with prostate cancer receiving androgen deprivati...